Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Epizyme's Business Segments
Epizyme's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 28
Regions Reported
-
Epizyme does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Collaboration and Other Revenue59.9%
- Manufacturing Material13.8%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration and Other Revenue | $ 16 | 59.9% |
| Manufacturing Material | $ 4 | 13.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Epizyme
Epizyme Inc. is a publicly traded biopharmaceutical company that focuses on developing novel precision medicines for the treatment of a variety of genetically driven cancers and other diseases. The company was founded in 2007 and has since become a leader in the field of epigenetics.
Epizyme's primary mission is to harness the power of epigenetics, which involves the study of changes in gene expression or cellular phenotype that do not involve alterations in the underlying DNA sequence. By targeting epigenetic enzymes and other proteins involved in epigenetic processes, Epizyme aims to develop innovative therapies that can potentially change the course of challenging diseases.
The company's most advanced product candidate is tazemetostat, an oral small molecule inhibitor of the EZH2 protein. EZH2 is an enzyme that plays a critical role in various forms of cancer and is frequently found to be overexpressed or mutated in several types of tumors. Tazemetostat has shown potential in clinical trials for the treatment of patients with certain types of solid tumors and hematologic malignancies.
Epizyme's extensive research and development efforts have also resulted in the discovery of additional potential therapeutic candidates. These include EZM8266, an inhibitor of protein methyltransferase DOT1L aimed at treating acute leukemia, and EZM8931, a selective inhibitor of the PRMT5 protein for the treatment of solid tumors.
To advance their drug candidates, Epizyme collaborates with various partners, including pharmaceutical companies, academic institutions, and research organizations. The company has established partnerships with leading companies such as GlaxoSmithKline, Sanofi, and Celgene (now part of Bristol Myers Squibb), which further validates the potential of Epizyme's drug discovery platform.
As a testament to its success, Epizyme has received multiple awards and recognition for its accomplishments. Notably, it was named one of FierceBiotech's Fierce 15 biotech companies in 2016, 2018, and 2019, highlighting its innovative approach and transformative impact in the biotech industry.
In addition to its commitment to developing breakthrough therapies, Epizyme is also involved in improving patient access to their medicines. The company collaborates with various patient advocacy groups, healthcare providers, and policy organizations to create programs that enhance patient support and reduce barriers to treatment.
Epizyme is headquartered in Cambridge, Massachusetts, and employs a team of dedicated scientists, researchers, and professionals who are passionate about transforming the lives of patients with genetically driven cancers and other diseases. With its robust pipeline of potential therapeutics and strong industry partnerships, Epizyme continues to push the boundaries of epigenetic medicine and drive towards its vision of delivering precision therapies to patients in need.
Epizyme's primary mission is to harness the power of epigenetics, which involves the study of changes in gene expression or cellular phenotype that do not involve alterations in the underlying DNA sequence. By targeting epigenetic enzymes and other proteins involved in epigenetic processes, Epizyme aims to develop innovative therapies that can potentially change the course of challenging diseases.
The company's most advanced product candidate is tazemetostat, an oral small molecule inhibitor of the EZH2 protein. EZH2 is an enzyme that plays a critical role in various forms of cancer and is frequently found to be overexpressed or mutated in several types of tumors. Tazemetostat has shown potential in clinical trials for the treatment of patients with certain types of solid tumors and hematologic malignancies.
Epizyme's extensive research and development efforts have also resulted in the discovery of additional potential therapeutic candidates. These include EZM8266, an inhibitor of protein methyltransferase DOT1L aimed at treating acute leukemia, and EZM8931, a selective inhibitor of the PRMT5 protein for the treatment of solid tumors.
To advance their drug candidates, Epizyme collaborates with various partners, including pharmaceutical companies, academic institutions, and research organizations. The company has established partnerships with leading companies such as GlaxoSmithKline, Sanofi, and Celgene (now part of Bristol Myers Squibb), which further validates the potential of Epizyme's drug discovery platform.
As a testament to its success, Epizyme has received multiple awards and recognition for its accomplishments. Notably, it was named one of FierceBiotech's Fierce 15 biotech companies in 2016, 2018, and 2019, highlighting its innovative approach and transformative impact in the biotech industry.
In addition to its commitment to developing breakthrough therapies, Epizyme is also involved in improving patient access to their medicines. The company collaborates with various patient advocacy groups, healthcare providers, and policy organizations to create programs that enhance patient support and reduce barriers to treatment.
Epizyme is headquartered in Cambridge, Massachusetts, and employs a team of dedicated scientists, researchers, and professionals who are passionate about transforming the lives of patients with genetically driven cancers and other diseases. With its robust pipeline of potential therapeutics and strong industry partnerships, Epizyme continues to push the boundaries of epigenetic medicine and drive towards its vision of delivering precision therapies to patients in need.
Epizyme Inc. specializes in the development of epigenetic therapies aimed at treating various forms of cancer. The company focuses on leveraging its expertise in the understanding of the epigenome, which plays a crucial role in regulating gene expression and maintaining cellular functions. Their therapeutic strategy is primarily centered around small molecule drugs that target specific enzymes involved in epigenetic regulation.
Segments
1. Oncology: The primary focus of Epizyme is in the oncology segment, where the company is dedicated to discovering and developing treatments for patients with hematological malignancies and solid tumors. The companys research is rooted in the understanding of how epigenetic changes can lead to cancer, and they aim to reverse these changes through targeted therapies.
2. Research and Development: Epizyme invests significantly in R&D to discover new therapeutic candidates and to expand its pipeline. This encompasses preclinical development, clinical trials, and collaborative research with academic institutions and other biotech firms focused on epigenetic pathways.
Products
1. Tazemetostat (Abramen): This is Epizymes lead product candidate, a potent and selective inhibitor of the EZH2 enzyme, which is part of the Polycomb Repressive Complex 2 (PRC2). Tazemetostat has shown promise in treating various types of cancer, particularly those with mutations in the EZH2 gene or alterations in the PRC2 complex. It is utilized in the treatment of relapsed or refractory follicular lymphoma and other malignancies.
2. Pipeline Products: In addition to Tazemetostat, Epizyme is developing several other product candidates targeting various epigenetic modifications. These candidates aim to tackle diverse solid tumors and hematological malignancies associated with abnormal epigenetic regulation.
3. Combinations and Collaborations: Epizyme is actively exploring combination therapies that pair its epigenetic drugs with existing oncology treatments, including chemotherapies and immunotherapies. This approach aims to enhance the efficacy of its therapies and address drug resistance.
Services
1. Clinical Trial Services: Epizyme conducts clinical trials to assess the safety and efficacy of its drug candidates. These trials include Phase 1, Phase 2, and potentially Phase 3 studies, involving patient recruitment, data management, and regulatory compliance.
2. Partnerships and Collaborations: The company may engage in strategic partnerships with other biopharmaceutical firms, academic institutions, and research organizations to collaborate on research and development initiatives. These partnerships enable the sharing of resources, knowledge, and expertise, fostering innovation in epigenetic therapies.
3. Patient and Healthcare Provider Education: Epizyme places importance on educating healthcare providers and patients about its therapies, including the science behind epigenetics and the specific indications for their products. This service may include the provision of educational materials, clinical data publication, and insights into the mechanisms of action of their therapies.
Conclusion
Epizyme Inc. is at the forefront of epigenetic research, focusing on innovative therapeutic approaches to treat cancer. Their dedication to understanding the molecular mechanisms of cancer through the lens of epigenetics is reflected in their product pipeline and strategic endeavors. The company continues to explore and expand its therapeutic offerings while actively engaging with the broader scientific and medical communities to pave the way for future advancements in cancer treatment.
Segments
1. Oncology: The primary focus of Epizyme is in the oncology segment, where the company is dedicated to discovering and developing treatments for patients with hematological malignancies and solid tumors. The companys research is rooted in the understanding of how epigenetic changes can lead to cancer, and they aim to reverse these changes through targeted therapies.
2. Research and Development: Epizyme invests significantly in R&D to discover new therapeutic candidates and to expand its pipeline. This encompasses preclinical development, clinical trials, and collaborative research with academic institutions and other biotech firms focused on epigenetic pathways.
Products
1. Tazemetostat (Abramen): This is Epizymes lead product candidate, a potent and selective inhibitor of the EZH2 enzyme, which is part of the Polycomb Repressive Complex 2 (PRC2). Tazemetostat has shown promise in treating various types of cancer, particularly those with mutations in the EZH2 gene or alterations in the PRC2 complex. It is utilized in the treatment of relapsed or refractory follicular lymphoma and other malignancies.
2. Pipeline Products: In addition to Tazemetostat, Epizyme is developing several other product candidates targeting various epigenetic modifications. These candidates aim to tackle diverse solid tumors and hematological malignancies associated with abnormal epigenetic regulation.
3. Combinations and Collaborations: Epizyme is actively exploring combination therapies that pair its epigenetic drugs with existing oncology treatments, including chemotherapies and immunotherapies. This approach aims to enhance the efficacy of its therapies and address drug resistance.
Services
1. Clinical Trial Services: Epizyme conducts clinical trials to assess the safety and efficacy of its drug candidates. These trials include Phase 1, Phase 2, and potentially Phase 3 studies, involving patient recruitment, data management, and regulatory compliance.
2. Partnerships and Collaborations: The company may engage in strategic partnerships with other biopharmaceutical firms, academic institutions, and research organizations to collaborate on research and development initiatives. These partnerships enable the sharing of resources, knowledge, and expertise, fostering innovation in epigenetic therapies.
3. Patient and Healthcare Provider Education: Epizyme places importance on educating healthcare providers and patients about its therapies, including the science behind epigenetics and the specific indications for their products. This service may include the provision of educational materials, clinical data publication, and insights into the mechanisms of action of their therapies.
Conclusion
Epizyme Inc. is at the forefront of epigenetic research, focusing on innovative therapeutic approaches to treat cancer. Their dedication to understanding the molecular mechanisms of cancer through the lens of epigenetics is reflected in their product pipeline and strategic endeavors. The company continues to explore and expand its therapeutic offerings while actively engaging with the broader scientific and medical communities to pave the way for future advancements in cancer treatment.